Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen receptor axis have significantly delayed disease progression. However, drug ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated its award-winning ArteraAI Prostate Test with new insights to help ...

Abiraterone with discontinuation of gonadotropin-releasing hormone (GnRH) analogues in patients (pts) with metastatic prostate cancer (PC): Survival results from a single-arm, phase II study. Matan ...

In the United Kingdom, abiraterone has been approved in Scotland and Wales to treat newly-diagnosed, high-risk prostate cancer that has not yet spread, but in England, it is only available through ...

Background: Abiraterone and ARPIs, including enzalutamide and apalutamide, in combination with androgen deprivation therapy (ADT), are standard treatments for metastatic castration - sensitive ...